Who is sponsoring NCT01829464?

NCT01829464 is sponsored by Takeda.

What drugs are being tested in NCT01829464?

Interventions: Placebo, TAK-875, TAK-875.

What is the status of NCT01829464?

NCT01829464 is currently TERMINATED.

Last reviewed 2016-04-24 · How we verify

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes

NCT01829464 Phase 3 TERMINATED Results posted

The purpose of this study is to evaluate the effect of TAK-875 (fasiglifam) in combination with sitagliptin on glycemic control in adults with type 2 diabetes.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	TERMINATED
Enrolment	90
Start date	2013-05
Completion	2014-03

Conditions

Diabetes

Interventions

Placebo
TAK-875
TAK-875

Primary outcomes

Change From Baseline in HbA1c at Week 24 — Baseline and Week 24
The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24 relative to baseline.

Countries

United States, Argentina, Peru